Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis

Zoé Van de Wyngaert; Irene Romera-Martinez; Céline Chedeville; Paolo Musiu; Souhila Ikhlef; Bénédicte Jonca; Mohamad Mohty; Florent Malard

doi:10.46989/001c.116800

Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis

Clin Hematol Int. 2024 May 6;6(2):46-50. doi: 10.46989/001c.116800. eCollection 2024.

Authors

Zoé Van de Wyngaert^{1

2}, Irene Romera-Martinez², Céline Chedeville², Paolo Musiu², Souhila Ikhlef², Bénédicte Jonca³, Mohamad Mohty^{1

2}, Florent Malard^{1

2}

Affiliations

¹ Sorbonne Université ; Centre de Recherche Saint-Antoine INSERM UMRs938.
² Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
³ Service de médecine nucléaire Tenon Hospital.

Abstract

We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell maturation antigen (BCMA)xCD3 bispecific antibody proved to be feasible, without unexpected side effects. Increased attention to infectious risk is crucial for these doubly fragile patients.

Keywords: BCMA; bispecifics; dialysis; elranatamab; multiple myeloma.

Publication types

Case Reports